The Clorox Company (NYSE:CLX) Stock Position Trimmed by Bridges Investment Management Inc.

Bridges Investment Management Inc. decreased its position in The Clorox Company (NYSE:CLX) by 2.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,872 shares of the company’s stock after selling 200 shares during the period. Bridges Investment Management Inc.’s holdings in Clorox were worth $1,445,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in CLX. Vanguard Group Inc. grew its holdings in Clorox by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 15,277,580 shares of the company’s stock worth $2,339,150,000 after buying an additional 48,632 shares in the last quarter. Nuance Investments LLC increased its holdings in shares of Clorox by 150.6% during the second quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock valued at $218,035,000 after purchasing an additional 960,094 shares during the period. Van ECK Associates Corp raised its stake in shares of Clorox by 2.2% during the third quarter. Van ECK Associates Corp now owns 1,492,717 shares of the company’s stock valued at $237,372,000 after purchasing an additional 31,510 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Clorox by 14.4% during the second quarter. Bank of New York Mellon Corp now owns 961,387 shares of the company’s stock valued at $131,200,000 after purchasing an additional 120,716 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Clorox by 26.5% in the first quarter. Acadian Asset Management LLC now owns 882,526 shares of the company’s stock worth $135,099,000 after purchasing an additional 184,847 shares during the period. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Stock Performance

Shares of CLX opened at $165.16 on Friday. The company has a 50-day moving average of $162.14 and a two-hundred day moving average of $146.83. The stock has a market cap of $20.44 billion, a price-to-earnings ratio of 57.55, a PEG ratio of 3.01 and a beta of 0.41. The company has a debt-to-equity ratio of 11.08, a current ratio of 1.00 and a quick ratio of 0.62. The Clorox Company has a one year low of $127.60 and a one year high of $169.09.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.50. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The firm had revenue of $1.76 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same quarter last year, the business posted $0.49 EPS. The company’s revenue was up 27.0% on a year-over-year basis. On average, equities research analysts expect that The Clorox Company will post 6.85 earnings per share for the current year.

Clorox Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, November 7th. Investors of record on Wednesday, October 23rd were given a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend was Wednesday, October 23rd. Clorox’s payout ratio is 170.04%.

Insider Buying and Selling

In other Clorox news, EVP Angela C. Hilt sold 1,733 shares of Clorox stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $165.52, for a total transaction of $286,846.16. Following the transaction, the executive vice president now owns 13,471 shares of the company’s stock, valued at $2,229,719.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.57% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on CLX. Evercore ISI dropped their price target on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a research report on Monday, October 14th. Barclays boosted their target price on Clorox from $137.00 to $139.00 and gave the stock an “underweight” rating in a report on Friday, November 1st. JPMorgan Chase & Co. increased their price target on Clorox from $148.00 to $174.00 and gave the company a “neutral” rating in a research note on Friday, October 11th. DA Davidson boosted their price objective on Clorox from $153.00 to $171.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Finally, TD Cowen raised Clorox from a “sell” rating to a “hold” rating and raised their target price for the company from $155.00 to $170.00 in a research note on Wednesday. Five investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Clorox currently has an average rating of “Hold” and an average target price of $155.00.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.